Priveterra Acquisition Corp. (PMGM) to Combine with AEON Biopharma in $201M Deal

Dec 13, 2022 Deal Announcements & Amendments, Headline Post, INTEL by Nicholas Alan Clayton

Priveterra (NASDAQ:PMGM) has entered into a definitive agreement to combine with drug developer AEON at an enterprise value of $201.8 million. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers. The combined company is expected to trade on the Nasdaq under the symbol “AEON” once
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Priveterra Acquisition Corp. (PMGM) to Combine with AEON Biopharma in $201M Deal

Priveterra Acquisition Corp. (PMGM) to Combine with AEON Biopharma in $201M Deal

ByNicholas Alan Clayton